Health
Empagliflozin reduces risk of death in patients with heart failure and reduced ejection fraction – News-Medical.Net
Empagliflozin reduces the risk of cardiovascular death or hospitalization for heart failure in patients with heart failure and a reduced ejection fraction.
Empagliflozin reduces the risk of cardiovascular death or hospitalization for heart failure in patients with heart failure and a reduced ejection fraction. That’s the finding of the EMPEROR-Reduced trial presented in a Hot Line session today at ESC Congress 2020.
The EMPEROR-Reduced trial was designed to evaluate the effects of empagliflozin 10 mg once daily (as compared with placebo) in patients with heart failure and a reduced ejection fraction, with or without diabetes, who were already rece…
-
General18 hours agoChina and Philippines trade blame over latest South China Sea clash
-
Noosa News22 hours agoBrisbane rising on global rankings, but still behind southern capitals
-
General18 hours agoSmall plane crashes into San Diego neighbourhood, setting homes and vehicles on fire
-
Noosa News8 hours agoTully Sugar Mill celebrates 100 years of cane harvesting amid floods and cyclones